pfizer_istock-458618835_no_limit_pictures--1

nono_limit_pictures / iStockphoto.com

30 January 2018Africa

Pfizer, patents and political quagmires

Shahan Islam said his enforcement efforts against generic producers often lead to counterarguments surrounding the price of Pfizer’s drugs and accusations that the company does not provide sufficient access to medicine for poorer people.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

‘Don’t stifle UK AI innovation’: King's speech on AI Act prompts warnings

Novo Nordisk’s uphill battle in the counterfeit weight loss craze

FTC supports USPTO terminal disclaimer plan amid opposition

BlueAllele says rival gained $100m from Regeneron deal using patented tech